Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 129 | 30 | 97 |
| Samples | 127 | 30 | 95 |
| Peptides | 71 | 17 | 58 |
Function
CST9L · Cystatin 9 like
The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions. The cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes. This gene is located in the cystatin locus and encodes a protein similar to mouse cystatin 9. Based on its testis-specific expression, it is likely to have a role in tissue reorganization during early testis development. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000376979 | Q9H4G1 | 129 | 71 |
Gene Properties
Recurrent Mutations
All 71 amino-acid changes on canonical ENST00000376979 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CST9L · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CST9L – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Melanoma | 4/210 2% | 19/1899 1% |
| Endometrial Carcinoma | 1/42 2% | 6/612 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 4/1390 0% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Neuroendocrine Tumour | 3/154 2% | 1/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Colorectal Carcinoma | 5/143 4% | 10/3239 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Other Solid Cancers | 1/94 1% | 5/1515 0% |
| Hepatocellular Carcinoma | 0/46 0% | 6/2210 0% |
| Ovarian Carcinoma | 0/109 0% | 3/998 0% |
| Gastric Carcinoma | 1/74 1% | 4/1809 0% |
| Breast Carcinoma | 3/144 2% | 6/3264 0% |
| Head and Neck Carcinoma | 1/85 1% | 2/1574 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Prostate Carcinoma | 0/13 0% | 2/2105 0% |
| Glioma | 0/52 0% | 2/2127 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 1/2534 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 1/2550 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 0/2640 0% |
Mutation Distribution
Where CST9L is mutated · all tissues, split by cell line vs tissue
How many mutations in CST9L were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 2 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 129 mutations in CST9L
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|